CELESTONE SOLUSPAN Rx
Generic Name and Formulations:
Betamethasone sodium phosphate 3mg/mL, betamethasone acetate 3mg/mL; susp for IM, intra-articular or intralesional inj; contains benzalkonium chloride.
Merck & Co., Inc.
Indications for CELESTONE SOLUSPAN:
Steroid-responsive disorders when oral therapy not feasible.
See full labeling. Individualize. Titrate to lowest effective dose. Usual range: 0.25–9mg/day.
See full labeling. Individualize. Titrate to lowest effective dose. Initially 0.02–0.3mg/kg/day in 3 or 4 divided doses.
IM inj with idiopathic thrombocytopenic purpura.
Avoid IV administration. Not for treating traumatic brain injury or optic neuritis. Not for epidural use; serious neurologic events may occur. Concomitant systemic fungal infections, active ocular herpes simplex, cerebral malaria, live vaccines, previously injected joint: not recommended. Latent or active amebiasis. Strongyloides infection. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. CHF. Recent MI. Hypertension. Fluid retention. Renal insufficiency. Peptic ulcers. Diverticulitis. Intestinal anastomoses. Ulcerative colitis. Cirrhosis. Unstable or infected joints. Postmenopausal women (osteoporosis risk). Supplement with additional steroids in physiologic stress. Emotional instability. Psychotic tendencies. Myasthenia gravis. Avoid abrupt cessation. Monitor thyroid, weight, growth, fluid, electrolyte balance and intraocular pressure (w. therapy >6weeks). Pregnancy (Cat.C). Nursing mothers.
Potentiated by ketoconazole, macrolides, cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine. May potentiate cyclosporine (seizure risk). May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin, other NSAIDs. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Concomitant neuromuscular blocking agents; increased risk of myopathy. Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, hypokalemia, hypocalcemia, hypernatremia, hypertension, thromboembolic disorders, psychic disorders, myopathy, osteoporosis, nausea, pancreatitis, peptic ulcer, dermal atrophy, increased sweating, impaired wound healing, increased intracranial pressure, carbohydrate and glucose intolerance, weight gain, inj site reactions, Kaposi's sarcoma, anaphylactoid reactions.
Multi-dose vial (5mL)—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Researchers Identify Novel Potential Biomarkers for Autism
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Triiodothyronine in the Treatment of Bipolar Depression
- Suicide Risk After Self-Harm Among Adolescents, Young Adults
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Safety, Efficacy of Deep Brain Stimulation for Alzheimer Disease Examined
- Many Teens Who Use Tobacco Don't Self-Identify as Users